M&A Deal Summary

Assertio Acquires Otrexup

On December 15, 2021, Assertio acquired life science company Otrexup from Antares Pharma for 44M USD

Acquisition Highlights
  • This is Assertio’s 2nd transaction in the Life Science sector.
  • This is Assertio’s 3rd largest (disclosed) transaction.
  • This is Assertio’s 3rd transaction in the United States.
  • This is Assertio’s 1st transaction in New Jersey.

M&A Deal Summary
Date 2021-12-15
Target Otrexup
Sector Life Science
Buyer(s) Assertio
Sellers(s) Antares Pharma
Deal Type Divestiture
Deal Value 44M USD

Target

Otrexup

New Jersey, United States
Otrexup is a drug-device combination single dose once weekly auto-injector containing a prescription medicine, methotrexate, which is indicated for certain adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis (pJIA), after treatment with other medicines including non-steroidal anti-inflammatory drugs (NSAIDS) have been used and did not work well. It is also used to control the symptoms of severe, resistant, disabling psoriasis in adults when other types of treatment have been used and did not work well.

Search 198,242 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Assertio

Lake Forest, Illinois, United States
Category Company
Founded 1995
Sector Life Science
Employees53
Revenue 152M USD (2023)
DESCRIPTION

Assertio is a pharmaceutical company focused on products to treat pain and other central nervous system (CNS) conditions. Assertio was founded in 1995 and is based in Lake Forest, Illinois.

DEAL STATS #
Overall 3 of 4
Sector (Life Science) 2 of 3
Type (Divestiture) 2 of 2
State (New Jersey) 1 of 1
Country (United States) 3 of 4
Year (2021) 1 of 1
Size (of disclosed) 3 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2020-03-16 Zyla Life Sciences

Wayne, Pennsylvania, United States

Zyla Life Sciences is a business committed to bringing important products to patients and healthcare providers. Zyla is focused on marketing its portfolio of medicines for pain and inflammation. Zyla Life Sciences portfolio includes six products: SPRIX® (ketorolac tromethamine) Nasal Spray, ZORVOLEX® (diclofenac), VIVLODEX® (meloxicam), INDOCIN® (indomethacin) suppositories, INDOCIN® oral suspension and OXAYDO® (oxycodone HCI, USP) tablets for oral use only - CII. Zyla Life Sciences was founded in 2010 and is based in Wayne, Pennsylvania.

Buy -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2023-04-25 Spectrum Pharmaceuticals

Boston, Massachusetts, United States

Spectrum Pharmaceuticals is a biotechnology company focused on acquiring, developing and commercializing drug products with a primary focus in oncology and hematology. Spectrum Pharmaceuticals was founded in 1987 and is based in Boston, Massachusetts.

Buy $248M

Seller(S) 1

SELLER

Antares Pharma

Ewing, New Jersey, United States
Category Company
Founded 1978
Sector Life Science
Revenue 184M USD (2021)
DESCRIPTION

Antares Pharma is a developer of self-administered parenteral pharmaceutical products using advanced drug delivery auto-injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development. Antares Pharma was founded in 1978 and is based in Ewing, New Jersey.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
State (New Jersey) 1 of 1
Country (United States) 1 of 1
Year (2021) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2019-11-19 Idorsia Pharmaceuticals

Allschwil, Switzerland

Idorsia Pharmaceuticals Ltd. is a developer of selatogrel, a potent, fast-acting, reversible, and highly-selective P2Y12 receptor antagonist, for single subcutaneous self-administration for the treatment of a suspected AMI in patients with a history of AMI. Idorsia has previously announced that two Phase 2 studies in patients with stable coronary artery disease and acute myocardial infarction, respectively, have met their pharmacodynamic objectives of significantly inhibiting platelet aggregation. Idorsia Pharmaceuticals is based in Allschwil, Switzerland.

Buy -
Mergr

Product

Company

Legal